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New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This
multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy in intermediate and poor prognosis MGCT
(IGCCCG criteria). C-BOP/BEP treatment consisted of cycles of cisplatin, vincristine, bleomycin and carboplatin, followed by one
cycle of vincristine and bleomycin and three cycles of BEP (bleomycon, etoposide, cisplatin). The trial was designed to demonstrate a
1-year progression-free survival rate of 80%, that is, to exclude a 1-year rate of 70% or less, with a one-sided significance level of 5%.
Secondary end points included toxicity, overall survival and the postchemotherapy complete response rate. In total, 16 European
hospitals entered 66 eligible patients (intermediate prognosis group: 37; poor prognosis group: 29). A total of 45 patients (68.2%,
95% confidence interval (95% CI): 56.9–79.4%) achieved a complete response (intermediate prognosis: 30; poor prognosis: 15).
After a median observation time of 40.4 months (range: 13.7–66.3), the 1-year progression-free survival rate was 81.8% 95% CI:
72.5–91.1%). The 2-year overall survival was 84.5% (95% CI: 75.6–93.3%). In all, 51 patients experienced at least one episode of
WHO grade 3/4 leucopenia, and at least one event of grade 3/4 thrombocytopenia occurred in 30 patients. There was no toxic
death. With an 82% 1-year progression-free survival and a lower limit of the 95% CI above 70%, the efficacy of C-BOP/BEP is
comparable to that of published alternative chemotherapy schedules in high-risk MGCT patients. The treatment’s toxicity is
manageable in a multicentre setting. In poor prognosis patients, C-BOP/BEP should be compared to standard chemotherapy of four
cycles of BEP.
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In patients with metastatic germ cell tumour (MGCT), four cycles
of BEP regimen (bleomycin, etoposide, cisplatin) are considered to
be the standard chemotherapy, even in patients belonging to the
intermediate and poor prognosis groups defined by the Interna-
tional Germ Cell Collaborative Consensuses Group (ICCCCG)
(IGCCCG, 1997). Nevertheless, many attempts have been under-
taken to improve the outcome of these patients by the introduction
of new chemotherapeutic agents, the use of alternating drug
combinations, high-dose chemotherapy schedules or chemother-
apy schedules that apply drugs at high density (Table 1). Several
research groups have retrospectively categorised their patients by
the IGCCCG classification system and have demonstrated survival
rates superior to those shown in the first report of the IGCCCG for
patients belonging to the poor prognosis group.
Based on the schedule described by Wettlaufer et al (1984), the
Royal Marsden Hospital in the late 1980s started to develop an
‘intensive induction regimen’ in an effort to overcome rapid
tumour cell proliferation (Horwich et al, 1989a, 1994b). During the
first 4 weeks, cisplatin, vincristine and bleomycin (BOP) were
administered with a 7-day interval, followed by a further two cycles
of bleomycin and vincristine (BO), and thereafter by three cycles of
BEP. The final C-BOP/BEP regimen contained a moderate dose of
carboplatin (C) in order to achieve a higher total dose of platinum
without increasing toxicity. Of 21 patients treated between 1989
and 1992 at the Royal Marsden, 18 were still alive and disease free
after a follow-up of 36 months, resulting in a 2-year survival of
90%. A subsequent extended phase II study confirmed the
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spromising single-centre results in 54 patients with unfavourable
risk using the Royal Marsden classification system (Christian et al
(2003)). This trial performed in three experienced oncological
units documented survival rates that were comparable to those
achieved by the use of high-dose chemotherapy with autologous
haematological stem cell support (Schmoll et al, 2003).
Based on these promising results, a prospective multicentre trial
using the C-BOP/BEP regimen seemed warranted in patients
belonging to the intermediate- and high-risk groups categorised
according to the international classification system. Therefore,
in 1998, the EORTC GU group decided to further assess the
C-BOP/BEP chemotherapy schedule with the aim, in a prospective
multicentre setting, to evaluate the regimen’s feasibility and
toxicity, to estimate the complete response rate and to establish
the progression-free and overall survival.
PATIENTS AND METHODS
Patients
Eligible patients had histologically confirmed germ cell cancer
(seminoma or nonseminoma) and had to be of intermediate or
poor prognosis according to the IGCCCG classification system.
They should be aged between 18 and 65 years, without major organ
dysfunction unless caused by the malignant disease. All patients
had to give informed consent, and consent from local ethical
boards had to be obtained. Patients with previous chemotherapy
and/or a second malignancy, except a basal cell skin cancer, were
ineligible as were those with a creatinine clearance below 40ml/
min, unless this was due to obstructive uropathy which could be
relieved by nephrostomy or stenting. Previous radiotherapy was
not an exclusion criterion.
Pretreatment evaluation
Pretreatment evaluation comprised physical examination, CT
scanning of the abdomen and chest, measurement of serum
alpha-foetoprotein (AFP), human choriogonadotropin (HCG) and
lactate dehydrogenase (LDH). A CT scan or an MRI scan of the
brain had to be performed in patients presenting with CNS
symptoms, those with a serum HCG 41 10
5IU/l or in patients
with more than 20 lung metastases.
Study design
All patients had to be registered at the EORTC Data Center in
Brussels before the onset of chemotherapy or latest within the first
2 weeks after start. Chemotherapy comprised an initial intensive
induction phase with C-BOP/BO for 6 weeks followed by three
3-weekly cycles of BEP with reduced doses of bleomycin (Table 2).
Table 1 Chemotherapy and outcome in patients with metastatic germ cell tumours belonging to the intermediate- and high-risk group (IGCCCG criteria)
Progr.-free survival Overall survival
Year Author Treatment
No. of
Institutions
No. of
Patients CR rate (%)
Interval
(years) Per cent (%)
Interval
(years) Per cent (%)
Intermediate prognostic group
1997 IGCCCG Multiple mostly ‘conventional’ B30 1524 NA 5 75 5 79
1997 Bower POMB/ACE 2 41 NA NA NA 3 88
2001 Sonnenveld Multiple 1 105 NA NA NA 10 1977–1986: 74
1987–1996: 87
2002a Fizazi CISCA/VB 1 38 NA NA NA 5 88
2002b Fizazi BOP-CISCA 1 19 NA 3 83 3 83
POMB-ACE
2003 Hinton BEP or VIP 5 84 NA 5 BEP: 84 5 BEP: 84
VIP: 72 VIP: 77
2004 Anthoney BOP/BEP 4 27 52 3 79 3 75
2005 Current C-BOP/BOP 16 37 76 2 90 2 89
Poor prognostic group
1997 IGCCCG Multiple mostly ‘conventional’ B30 821 NA 5 41 5 48
1997 Bower POMB/ACE 2 92 NA NA NA 3 75
1999 Germa/Lluch POMB-Epi 11 22 49 2 58 2 64
1999 DeWit Taxol/BEP 13 2 100 1.5 100 1.5 100
2000 Decatris BEP-CEC 1 20 NA NA NA 4 66
2001 Sonnenveld Multiple 1 49 NA NA NA 10 1977–1986: 30
X1986–1996: 62
Total: 42
2002a Fizazi CISCA/VB 1 NA NA NA NA 5 83
2002b Fizazi BOP-CISCA 1 38 NA 3 65 3 67
POMB-ACE
2003 Hinton BEP or VIP 5 57 NA 5 BEP: 49 5 BEP: 57
VIP: 56 VIP: 62
2003 Schmoll VIP-high dose 25 182 66 2 69 2 79
(85)
2003 Huddart CBOP-BEP 3 54 30 3 83 3 88
2004 Anthoney BOP-BEP 4 19 NA 3 84 5 65
2004 Rosti Carbo-PEC+Others+high
dose
6 22 76 2 67 2 81
2005 Current CBOP-BEP 16 29 56 2 56 2 78
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sThe C-BOP phase consisted of two identical 2-week cycles. The
carboplatin dose applied on day 8 of these 2-week cycles was in
milligrams: 3 (GFR (glomerular filtration rate)þ25). Bleomycin
15mg was applied over 15min on days 1 and 8. During days 8–12,
a total of 75mg bleomycin was given as continuous infusion
(15mgday
 1). The two C-BOP cycles were, after 2 weeks, followed
by cycle 3, consisting of bleomycin and vincristine. Cycles 4, 5 and
6 of BEP chemotherapy, given with reduced doses of bleomycin
(45mgcycle
 1), were applied at 3 weekly intervals. Dose reduc-
tions during the BEP cycle were planned only if there had been an
episode of neutropenic fever or sepsis in the previous cycle, in
which case the etoposide was given at 100mgm
 2 day
 1 for only 3
days during the following cycle.
After chemotherapy, all patients with nonseminomatous germ
cell tumours and normalised serum tumour markers, but with
evidence of residual disease, had to undergo resection of the
residual tumour masses. As 80–90% of the postchemotherapy
residual masses in patients with seminoma contain completely
necrotic tumour tissue and major surgery has been shown to be
somehow risky in these cases, routine postchemotherapy surgery
was not recommended in seminoma patients.
Response evaluation
Patients had to be evaluated for response within 4 weeks after
commencing cycle 6 or immediately after their postchemotherapy
surgery. Patients with normal tumour markers and no clinical or
radiological evidence of residual masses were classified as complete
responders. If ‘no tumour’, ‘necrosis only’ or ‘mature teratoma
only’ was detected in the completely resected specimen, the case
was also categorised as complete response.
Patients who after six cycles had persistently elevated tumour
markers, although reduced compared to the pretreatment values,
and/or who had residual vital malignant tumour in the operation
specimen belonged to the category of incomplete response.
Progression at any time after start of C-BOP/BEP was defined as
rising serum tumour markers above the upper limit of the
institution’s normal range or occurrence of new metatstatic lesions
or by a X25% size increase of pretreatment tumour masses.
The rare development of a growing teratoma, documented by
histological examination, represented an exception from this
definition. Patients who went off study before they had completed
the six cycles due to early death due to MGCT or due to
progression were categorised as treatment failures. Patients with
normal serum tumour markers after chemotherapy, but with
residual masses, who did not undergo postchemotherapy surgery
were regarded as inevaluable for response but were included in the
evaluation of the response rate.
Follow-up
Completely responding patients and those inevaluable for response
did not receive further treatment, whereas those with incomplete
response, treatment failure or progression were treated according
to the clinical investigator’s discretion. Data on type and outcome
of such salvage treatment were, however, not collected within the
trial.
All patients were to be followed-up for the event of progression.
Follow-up examinations were to be performed with 2–3-month
intervals during the first year and with increasing intervals
thereafter. Biopsy was recommended in seminoma patients with
residual masses if no size reduction had recurred after 6 months
observation. After progression, all patients were followed for
survival.
Statistical considerations
The primary trial end point was the 1-year progression-free
survival rate. The trial was designed to exclude a 1-year rate of 70%
or less with 95% confidence interval (95% CI) under the hypothesis
that the true rate was 80% (i.e. a lower limit of the 95% CI for the
1-year progression-free survival rate 470%). Under this condi-
tion, 62 evaluable patients had to be treated in this study. Using the
Kaplan–Meier technique, overall and progression-free survival
were calculated from the first day of chemotherapy to the date of
death (or progression) or to the date of most recent follow-up,
whichever came first.
Disclosure
This publication was supported by grant numbers 5U10-CA11488-
24 to 5U10-CA11488-35 from the National Cancer Institute
(Bethesda, Maryland, USA). Its contents are solely the responsi-
bility of the authors, and do not necessarily represent the official
views of the National Cancer Institute.
RESULTS
From June 1996 until March 1998, 16 institutions registered 79
patients; 13 of them were eventually deemed ineligible (registration
414 days after treatment start: 11; erroneous prognosis-group
classification: two). Of the 66 eligible patients, 39 belonged to the
intermediate prognosis group and 27 to the poor prognosis group
(Table 3). The median age of the 65 males and one female (ovarian
cancer) subject was 29 years (range 18–50). One patient in the
intermediate prognosis group had relapsed with bone metastases
after radiotherapy for stage 1 seminoma, and one patient with a
poor prognosis nonseminoma had radiotherapy 1 week before trial
entry due to imminent spinal cord compression. The median
observation time was 40.4 months (range: 13.7–66.3 months). All
but six patients were observed to death or a minimum of 2 years.
Treatment
Of the 66 patients, 62 received all six planned cycles (Table 4). One
patient died of progressive MGCT after the first cycle, and three
other men progressed after five treatment cycles. The relative
median cumulative dose of the four drugs of the C-BOP phase was
490% of the expected dose, as compared to 86% for each of
the three drugs of the BEP schedule. Dose modifications were
frequently required (postponement of at least one cycle: 33
patients; dose reduction during at least one cycle: seven patients;
Table 2 C-BOP/BEP treatment regimen
Cycles 1 and 2: C-BOP (2 weeks each)
Cisplatin 50mg/qm days 1 and 2
Vincristine 2mg i.v. days 1 and 8
Bleomycin 15mg days 1 and 8
Cisplatin 40mg/qm+carboplatin AUC 3 day 8
Bleomycin 15mg continuous infusion days 8–12
Cycle 3 BO (2 weeks)
Vincristine 2mg i.v., days 1 and 8
Bleomycin 15mg, days 1 and 8
Cycle 4,5,6: modified BEP (3 weeks each)
Cisplatin 20mg/m
2/day, days 1–5
Etoposide 100mg/m
2/day, days 1–5
Bleomycin 15mg, days 1, 8, 15
Weeks 1 ----- 4 5 6 7 10 13 17
C-BOP BO BO BEP BEP BEP7surgery/FU
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premature discontinuation of at least one cycle: 13 patients).
Overall, haematological toxicity was the most frequent reason
for dose modification (30 patients). Pulmonary and renal toxicity
led to dose modification in five and four patients, respectively.
Resections of postchemotherapy residual masses were performed
in 44 patients (intermediate-risk group: 25; high-risk group: 19).
Viable cancer cells were found in one patient from each risk group.
Of the 44 patients, 19 displayed postchemotherapy necrosis/
fibrosis, and 22 had mature teratoma (50%), without statistical
difference between the two subgroups as to histopathological
outcome.
Outcome
Immediately after chemotherapy or after their postchemotherapy
surgery, 45 of all 66 patients (68.2%, 95% CI: 56.9–79.4%) had a
complete response (intermediate group: 30 patients (76%); high-
risk group: 15 patients (56%)). Treatment failure was recorded in
the four patients who did not complete the six planned cycles.
Incomplete response was recorded in six patients, and 11 were
inevaluable for response. At the end of the observation time,
progression had occurred in a total of 17 patients (26%);
intermediate-risk group: five patients; high-risk group: 12 patients,
including the four patients with treatment failure. At the date of
last observation, 55 patients were alive and 11 were dead, 10 of
them due to their MGCT. (The 11th patient died tumour-free in a
car accident.)
The 1-year progression-free survival for all patients was 81.8%
(95% CI: 72.5–91.1%). The 2-year progression-free survival for the
Table 3 Patient characteristics
Risk group
Intermediate High Total
Number of patients entered 48 31 79
b
Ineligible
a 94 1 3
Eligible (years) 39 27 66
Age (median, range) 29 (18–50) 28 (18–41) 29 (18–50)
Site
Testis 35 17 52
Extragonadal 4 10 14
Retroperitoneal 4 4 8
Mediastinal 0 4 4
Other
b 02 2
Histology
Seminoma 2 0 2
Nonseminoma 37 27 64
Previous radiotherapy 1 1 2
Tumour sites at start of treatment
Abdominal LN
c 37 22 59
Mediastinal LN 5 11 16
Supraclav LN 4 3 7
Lung 16 13 29
Liver 0 9 9
Bone 1 0 1
Brain 0 2 2
Other 2 1 3
aOwing to registration 42 weeks after treatment start (11 patients) or inappropriate
serum marker values (2).
bOvary (1) and abdominal (1).
cLymph nodes.
Table 4 Maximal acute toxicity
Number of patients (%)
WHO 0–1 2 3 4
Haemoglobin 6 25 27 (40.9) 8 (12.1)
Neutrophils
a 43 3 9 (13.6) 9 (13.6)
Platelets 23 13 12 (18.2) 18 (27.3)
WBC 4 11 40 (60.6) 11 (16.7)
Infection 44 15 4 (6.1) 3 (4.5)
Febrile neutropenia 51 5 8 (12.1) 2 (3.0)
Mucositis 49 12 3 (4.5) 2 (3.0)
Ototoxicity
b 56 9
Sensory neuropathy 52 10 3 (4.5) 1 (1.5)
Pulmonary toxicity 57 5 2 (3.0) 2 (3.0)
Cutaneous toxicity 52 12 1 (1.5) 1 (1.5)
Any haematological toxicity 0 9 27 (4.9) 30 (45.5)
Any nonhaematological toxicity
c 8 25 25 (37.9) 8 (12.1)
Any toxicity
c 0 7 27 (40.9) 32 (48.5)
aMissing in two patients.
bMissing in one patient.
cAlso including fatigue, nausea,
vomiting, diarrhoea, constipation, other neurological toxicity and other side effects.
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Figure 1 Progression-free (A) and overall (B) survival in patients with
MGCT of the intermediate (37 patients) and poor prognosis (29 patients)
group.
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99.3%) and 55.6% (95% CI: 36.8–74.3%), respectively (Figure 1A).
The 1- and 2-year overall survivals were, respectively, 93.9% (95%
CI: 88.2–99.7%) and 84.5% (95% CI: 75.6–93.3%) (Figure 1B).
Toxicity
A total of 59 patients experienced grade 3 or 4 toxicity at least once
(Table 4). Grade 4 haematological toxicity was seen in 40.9% of the
patients, with thrombocytopenia being the most frequent side
effect. Four patients developed grade 3/4 pulmonary toxicity and
14 patients developed at least one period of grade 3/4 infection or
febrile neutropenia. There was no toxic death. G-CSF support was
administered at least once to 23 patients.
DISCUSSION
With an 81.8% observed 1-year progression-free survival and a
lower limit of the 95% CI above 70%, this phase II study reached
its target demonstrating results of a true 1-year progression-free
survival rate of 480%. The 2-year overall survival rates in,
respectively, intermediate and poor prognosis patients were 89 and
78%. The C-BOP/BEP schedule was feasible in a multicentre setting
with predictable and manageable short-term toxicity without any
toxic death.
In patients with metastatic germ cell tumours of unfavourable
prognosis, attempts to improve the outcome of the standard
regimen BEP as induction chemotherapy have focused on three
approaches: firstly, intensification of cisplatin application;
secondly, introduction of new drugs together with the sequential
use of alternating drug combinations; and thirdly, increasing the
cumulative doses of the cytotoxic, drugs including the use of high-
dose chemotherapy followed by autologous stem cell support. Not
rarely, clinical investigators have combined these strategies.
Intensification did not improve the 1-year failure-free survival
rate in the EORTC GU group’s phase III study that in poor
prognosis patients (Royal Marsden Hospital categorisation system)
compared three cycles of BOP (bleomycin, vincristine, cisplatin)
given every 10 days followed by three cycles of VIP-B (etoposide,
ifosfamide, cisplatin, bleomycin) with four cycles BEP plus two
cycles of EP (Kaye et al, 1998). Concerning the introduction of new
agents, four courses of VIP were compared with four cycles of
BEP (de Wit et al, 1998b), but both regimens led to similar 2-year
failure-free survival (VIP: 64%; BEP: 60%) and 2-year overall
survival (VIP: 74%; BEP: 71%). The greatest experience with the
use of alternative drugs has been with the POMB/ACE regimen
(cisplatin, vincristine, methotrexate,bleomycin, actinomycin-D,
cyclophosphamide, etoposide) with two institutions treating 339
patients with MGCT over a 20-year period with a median follow-up
of 8 years (Bower et al, 1997). In total, 92 patients were
retrospectively identified as IGCCC poor prognosis. The POMB-
EPI regimen, essentially consisting of the components of POMB
alternating with a modified VIP regimen, resulted in a 2-year
overall survival of 64% in 22 patients within the poor prognosis
group (Germa-Lluch et al, 1999). Taxanes in combination with
cisplatin-based chemotherapy have also been tested. In a phase I/II
study with BEP combined with Taxol, all 13 evaluable patients
with intermediate or poor prognosis MGCT achieved a complete
response and none of these patients relapsed with a median
follow-up of 18 months (de Wit et al, 1999a). Currently the EORTC
GU group conducts a phase III study comparing four cycles of
T-BEP with four cycles of BEP in patients with intermediate
prognosis features. Fizazi et al (2002a) reported a 5-year overall
survival of 88% in the intermediate prognosis group and 83%
(95% CI: 58–100%) in the poor prognosis group using the CISCA/
VB regimen (cisplatin, cyclophosphamide, adriamycin, vinblas-
tine, bleomycin). The same group described a phase II study using
the BOP-CISCA-POMB-ACE regimen comprising eight drugs plus
granulocyte colony-stimulating factor (Fizazi et al, 2002b).
Investigators of the Genitourinary Group of the French Federation
of Cancer Centers have embarked on a prospective trial of BEP vs
CISCA (II)/VB (IV) in poor-risk patients (Culine et al, 1997). The
third approach implies the attempts to use high-dose combination
chemotherapy with autologous haematopoetic stem cell support.
In several phase II trials, this strategy has resulted in promising
survival rates with acceptable toxicity without toxic death, for
example, given as CEC (cisplatin, etoposide, cyclophosphamide)
after induction with BEP (Decatris et al, 2000), or as sequential
high-dose VIP plus paclitaxel (Hartmann et al, 2002). The German
Testicular Cancer Group reported a 79% 2-year survival in 182
poor prognosis patients (IGCCCG criteria) who were treated with
escalating doses of VIP followed by autologous stem cell support
(Schmoll et al, 2003). In poor prognosis patients, high-dose
schedules using CEC or VIP together with autologous blood stem
cell transplantation are currently investigated in prospective
randomised trials by the US Intergroup (BEP vs high-dose CEC)
and the EORTC GU Group (BEP vs high-dose VIP).
The C-BOP/BEP schedule used in this study principally
comprises two manoeuvers to improve the efficacy of induction
chemotherapy during the first 6 weeks: an increase of the
cumulative cisplatin dose and frequent cycling of the cisplatin,
vincristine and bleomycin in an effort to overcome rapid
proliferation, together with alternating the C-BOP schedule with
BEP. For example, in the C-BOP schedule, the dose intensity of
platinum during the first 6 weeks is 63mgm
 2 week
 1 (based on a
carboplatin AUC3 being equivalent to cisplatin 50mgm
 2)
compared to 50mgm
 2 week
 1 in the BOP/VIP schedule and
33.3mgm
 2 week
 1 in the standard BEP. The results of the present
study are promising. When C-BOP/BEP is given in a multicentre
setting, the complete response rates and the 2-year overall survival
rates for, respectively, patients with intermediate and poor
prognosis MGCT is at least comparable with the results obtained
with other intensive cytotoxic regimens (Table 1). Our 2-year
overall survival in the poor prognosis group may seem slightly
inferior to Christian et al’s figure of 88% achieved at three large
cancer centres. This may be due to differences between poor
prognosis patients with MGCT as to the type and number of poor
risk factors (Decatris et al, 2000). Interstudy differences in
outcome may reflect differences in the prognostic features or
patient selection rather than real differences in treatment efficacy.
Christian et al’s slightly superior survival figure can also be viewed
as a consequence of broader experience with MGCT patients in
general at each of the three involved cancer centres as compared to
the experience of institutions with few cases of MGCT (Aass et al,
1991; Collette et al, 1999).
The C-BOP/BEP schedule has been shown to be safe in a
multicentre design, with no toxic deaths in the current study.
Based on nonrandomised historical studies (International Germ
Cell Cancer Collaborative Group, 1997), its superior efficacy
compared to BEP cannot be excluded. During the first weeks of the
induction chemotherapy, the proportion of myelotoxic drugs in C-
BOP is less than in the BEP schedule. This may be advantageous in
patients who are very sick due to a large tumour burden at the time
of diagnosis and who are at particularly high risk of neutropenic
fever and sepsis. Nevertheless, the occurrence of ‘any grade 3/4
toxicity’ in 90% of the patients and of grade 3/4 haematological
toxicity in 77% warrants that these patients should be managed at
institutions with experience in the treatment of MGCT.
Until the ongoing three phase III studies comparing four cycles
of BEP with experimental chemotherapy regimens are finalised,
BEP remains the standard treatment of MGCT, even in patients
with intermediate and poor prognosis features. The current and
published results with c-BOP/BEP support ongoing plans to
conduct a multicentre phase III study comparing C-BOP with
four cycles of BEP in poor prognosis patients.
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sContributions
The following investigators and centres contributed patients to the
study:
SD Fossa, Norwegian Radium Hospital, Oslo, Norway (21); B
Paluchowska, Maria Sklodowska – Curie Memorial Cancer Center,
Warsaw, Poland (16); A Horwich, Royal Marsden Hospital, Sutton,
UK (13); G Kaiser, Klinikum Nu ¨rnberg, Nu ¨rnberg, Germany (8);
P de Mulder, Sint Radboud University Hospital, Nijmegen, The
Netherlands (4); O Koriakine, Medical Radiological Research
Center, Obninsk, Russia (formerly: Cancer Research Center,
Moskow, Russia) (3); ATM Van Oosterom, Universitair Ziekenhuis
Gasthuisberg, Leuven, Belgium (3); C Sternberg, San Camillo and
Forlanini Hospitals (formerly: San Raffaele Hospital), Roma, Italy
(2); G Mead, Royal South Hants Hospitaln Southampton, UK (2);
JB Vermorken, Universitair Ziekenhuis Antwerpen, Edegem,
Belgium (1); JJ Croles, Bosh Medicentrum, s’Hertogenbosch, The
Netherlands (1); R de Wit, Erasmus Medical Center, Rotterdam,
The Netherlands (1); HJ Keizer, University Hospital, Leiden, The
Netherlands (1); A Bono, Ospedale di Circolo e Fundacione
Macchi, Varese, Italy (1); M Williams, Addenbrooke National
Health Service, Cambridge, UK (1); RE Coleman, Weston Park
Hospital, Sheffield, UK (1).
L de Prijck was the data manager at the EORTC Data Centre,
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